Boyer, David S.

Ranibizumab for Neovascular Age-Related Macular Degeneration

Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine

Retinal Diseases and TreatmentsRetinal and Macular Surgery

Cited by 5,886

Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON

Rofagha, S., Bhisitkul, R. B., Boyer, D. S., Sadda, S. R., & Zhang, K. (2013) · Ophthalmology

Retinal Diseases and TreatmentsOcular Diseases and Behçet’s Syndrome

Cited by 1,023

Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data

Spaide, R. F., Jaffe, G. J., Sarraf, D., Freund, K. B., Sadda, S. R., Staurenghi, G., Waheed, N. K., Chakravarthy, U., Rosenfeld, P. J., Holz, F. G., et al. (2020) · Ophthalmology

Retinal Diseases and TreatmentsRetinal Imaging and Analysis

Cited by 824

Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials

Heier, J. S., Lad, E. M., Holz, F. G., Rosenfeld, P. J., Guymer, R. H., Boyer, D., Grossi, F., Baumal, C. R., Korobelnik, J.-F., Slakter, J. S., et al. (2023) · The Lancet

Retinal Diseases and TreatmentsOcular Diseases and Behçet’s Syndrome

Cited by 520

Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: the SEVEN-UP study

Bhisitkul, R. B., Mendes, T. S., Rofagha, S., Enanoria, W., Boyer, D. S., Sadda, S. R., & Zhang, K. (2015) · American Journal of Ophthalmology

Retinal Diseases and TreatmentsRetinal and Macular Surgery

Cited by 210

Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): a prospective, two-year, multicentre phase 1 study

Khanani, A. M., Boyer, D. S., Wykoff, C. C., Regillo, C. D., Busbee, B. G., Pieramici, D., Danzig, C. J., Joondeph, B. C., Major, J. C., Turpcu, A., et al. (2024) · eClinicalMedicine

Retinal Diseases and TreatmentsRetinal Development and Disorders

Cited by 76

A randomized controlled trial of OPT-302, a VEGF-C/D inhibitor for neovascular age-related macular degeneration

Jackson, T. L., Slakter, J., Buyse, M., Wang, K., Dugel, P. U., Wykoff, C. C., Boyer, D. S., Gerometta, M., Baldwin, M. E., Price, C. F., et al. (2023) · Ophthalmology

Retinal Diseases and TreatmentsRetinal and Macular Surgery

Cited by 55

Outcomes of Eyes with Lesions Composed of >50% Blood in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT)

Altaweel, M. M., Daniel, E., Martin, D. F., Mittra, R. A., Grunwald, J. E., Lai, M. M., Melamud, A., Morse, L. S., Huang, J., Ferris, F. L., et al. (2015) · Ophthalmology

Retinal Diseases and TreatmentsRetinal Imaging and Analysis

Cited by 51

Current best clinical practices—management of neovascular AMD

Brown, D., Heier, J. S., Boyer, D. S., Freund, K. B., Kaiser, P., Kim, J. E., & Sarraf, D. (2017) · Journal of VitreoRetinal Diseases

Retinal Diseases and TreatmentsOcular Diseases and Behçet’s Syndrome

Cited by 23